HK$0.96 ($0.12)

-0.01 (-0.52%)

Weekly Expected Move ±3.7%

HK$1 HK$1 HK$1 HK$1 HK$1

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 46 · HK$1.9B mcap · 380M float · 0.086% daily turnover

Revenue

$1.6B +7.4% ▲

5Y CAGR: +0.1%

Gross Profit

$693M +11.7% ▲

5Y CAGR: +0.7%

Operating Income

$415M +24.5% ▲

5Y CAGR: +7.0%

Net Income

$301M +12.7% ▲

5Y CAGR: +6.9%

EPS (Diluted)

$0.15 +54.5% ▲

5Y CAGR: +6.4%

EBITDA

$559M +17.6% ▲

5Y CAGR: +2.9%

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$1.4B	$1.6B	$1.8B	$1.5B	$1.6B
YoY Growth	-8.0%	+10.3%	+11.9%	-17.8%	+7.4%
Cost of Revenue	$912M	$975M	$1.0B	$847M	$884M
Gross Profit	$534M	$621M	$747M	$620M	$693M
Gross Margin	36.9%	38.9%	41.8%	42.3%	43.9%
R&D Expenses	$2M	$7M	$1M	$0	$0
SG&A Expenses	$408M	$400M	$427M	$332M	$324M
Operating Expenses	$349M	$398M	$428M	$287M	$278M
Operating Income	$186M	$223M	$319M	$333M	$415M
Operating Margin	12.8%	14.0%	17.9%	22.7%	26.3%
Interest Expense	$30M	$26M	$61M	$79M	$41M
Income Before Tax	$226M	$235M	$343M	$255M	$374M
Tax Expense	$34M	$44M	$57M	$44M	$73M
Net Income	$174M	$178M	$251M	$267M	$301M
Net Margin	12.0%	11.1%	14.1%	18.2%	19.1%
EPS (Diluted)	$0.09	$0.09	$0.13	$0.10	$0.15
EBITDA	$377M	$415M	$462M	$475M	$559M
Shares Outstanding	1.92B	1.92B	1.91B	1.92B	1.99B

Line Item	FY2022 Q2	FY2022 Q4	FY2023 Q2	FY2023 Q4	FY2024 Q2	FY2024 Q4	FY2025 Q2	FY2025 Q4
Revenue	$817M	$968M	$715M	$753M	$810M	$767M	$767M	$803M
Cost of Revenue	$477M	$561M	$414M	$433M	$459M	$425M	$429M	$463M
Gross Profit	$340M	$407M	$301M	$319M	$351M	$341M	$338M	$340M
Gross Margin	41.7%	42.0%	42.1%	42.4%	43.4%	44.5%	44.1%	42.4%
R&D Expenses	$0	$2M	$0	$6M	$0	$0	$0	$0
SG&A Expenses	$188M	$240M	$163M	$170M	$165M	$159M	$169M	$156M
Operating Expenses	$188M	$240M	$163M	$152M	$156M	$159M	$169M	$156M
Operating Income	$152M	$167M	$138M	$167M	$196M	$182M	$169M	$184M
Operating Margin	18.6%	17.2%	19.4%	22.2%	24.2%	23.8%	22.0%	23.0%
Interest Expense	$22M	$45M	$47M	$31M	$21M	$21M	$13M	$18M
Income Before Tax	$179M	$165M	$119M	$136M	$175M	$198M	$174M	$189M
Tax Expense	$29M	$27M	$22M	$23M	$35M	$38M	$32M	$30M
Net Income	$136M	$115M	$126M	$113M	$140M	$161M	$142M	$160M
Net Margin	16.7%	11.9%	17.6%	15.0%	17.3%	20.9%	18.5%	19.9%
EPS (Diluted)	$0.07	$0.06	$0.07	$0.06	$0.07	$0.08	$0.07	$0.08
EBITDA	$294M	$301M	$200M	$248M	$255M	$291M	$260M	$262M
Shares Outstanding	1.92B	1.90B	1.91B	1.93B	1.98B	1.98B	2.00B	2.00B

2633.HK HKSE